Nuclear factor of activated T cells regulates osteopontin expression in arterial smooth muscle in response to diabetes-induced hyperglycemia

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 2, 2010, Pages 218-224

  Nilsson Berglund, Lisa M ^a   Zetterqvist, Anna V ^a   Nilsson Öhman, Jenny ^a   Sigvardsson, Mikael ^b   González Bosc, Laura V ^c   Smith, Maj Lis ^a   Salehi, Albert ^a   Agardh, Elisabet ^a   Fredrikson, Gunilla Nordin ^a   Agardh, Carl David ^a   Nilsson, Jan ^a   Wamhoff, Brian R ^d   Hultgårdh Nilsson, Anna ^e   Gomez, Maria F ^a  

^a LUND UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e LUND UNIVERSITY   (Sweden)

Author keywords

Diabetes; Hyperglycemia; Inflammation; NFAT; UTP; Vascular complications

Indexed keywords

A 285222; APYRASE; BETA ACTIN; CYCLOSPORIN A; GLUCOSE; LUCIFERASE; MESSENGER RNA; NUCLEOTIDE; OSTEOPONTIN; PROTEIN INHIBITOR; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY MUSCLE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE EXACERBATION; EX VIVO STUDY; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY MECHANISM; RESTENOSIS; RISK FACTOR; STREPTOZOCIN DIABETES; TRANSGENIC MOUSE;

ANIMALS; APYRASE; ARTERIES; BINDING SITES; BLOOD GLUCOSE; CALCINEURIN; CYCLOSPORINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; JURKAT CELLS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; NFATC TRANSCRIPTION FACTORS; OSTEOPONTIN; PROMOTER REGIONS, GENETIC; PYRAZOLES; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; URIDINE TRIPHOSPHATE;

EID: 75149179578     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.199299     Document Type: Article

References (38)

1. Ohmori R, Momiyama Y, Taniguchi H, Takahashi R, Kusuhara M, Nakamura H, Ohsuzu F. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis. 2003; 170:333-337.
2. Kato R, Momiyama Y, Ohmori R, Tanaka N, Taniguchi H, Arakawa K, Kusuhara M, Nakamura H, Ohsuzu F. High plasma levels of osteopontin in patients with restenosis after percutaneous coronary intervention. Arte-rioscler Thromb Vasc Biol. 2006;26:e1-e2.
3. Golledge J, Muller J, Shephard N, Clancy P, Smallwood L, Moran C, Dear AE, Palmer LJ, Norman PE. Association between osteopontin and human abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 2007; 27:655-660. (Pubitemid 46263414)
4. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arte-rioscler Thromb Vasc Biol. 2007;27:2302-2309.
5. Strom A, Franzen A, Wangnerud C, Knutsson AK, Heinegard D, Hultgardh-Nilsson A. Altered vascular remodeling in osteopontin-deficient atherosclerotic mice. J Vasc Res. 2004;41:314-322.
6. Matsui Y, Rittling SR, Okamoto H, Inobe M, Jia N, Shimizu T, Akino M, Sugawara T, Morimoto J, Kimura C, Kon S, Denhardt D, Kitabatake A, Uede T. Osteopontin deficiency attenuates atherosclerosis in female apo-lipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23: 1029-1034.
7. Chiba S, Okamoto H, Kon S, Kimura C, Murakami M, Inobe M, Matsui Y, Sugawara T, Shimizu T, Uede T, Kitabatake A. Development of atherosclerosis in osteopontin transgenic mice. Heart Vessels. 2002;16: 111-117.
8. Yamaguchi H, Igarashi M, Hirata A, Tsuchiya H, Sugiyama K, Morita Y, Jimbu Y, Ohnuma H, Daimon M, Tominaga M, Kato T. Progression of diabetic nephropathy enhances the plasma osteopontin level in type 2 diabetic patients. Endocr J. 2004;51:499-504.
9. Kase S, Yokoi M, Saito W, Furudate N, Ohgami K, Kitamura M, Kitaichi N, Yoshida K, Kase M, Ohno S, Uede T. Increased osteopontin levels in the vitreous of patients with diabetic retinopathy. Ophthalmic Res. 2007; 39:143-147.
10. Takemoto M, Yokote K, Nishimura M, Shigematsu T, Hasegawa T, Kon S, Uede T, Matsumoto T, Saito Y, Mori S. Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis. Arterioscler Thromb Vasc Biol. 2000;20: 624-628.
11. Martin AS, Du P, Dikalova A, Lassegue B, Aleman M, Gongora MC, Brown K, Joseph G, Harrison DG, Taylor WR, Jo H, Griendling KK. Reactive oxygen species-selective regulation of aortic inflammatory gene expression in Type 2 diabetes. Am J Physiol Heart Circ Physiol. 2007; 292:H2073-H2082.
12. Wang X, Louden C, Ohlstein EH, Stadel JM, Gu JL, Yue TL. Osteopontin expression in platelet-derived growth factor-stimulated vascular smooth muscle cells and carotid artery after balloon angioplasty. Arterioscler Thromb Vasc Biol. 1996;16:1365-1372. (Pubitemid 26378227)
13. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest. 1993;92:1686-1696.
14. Renault M-A, Jalvy S, Belloc I, Pasquet S, Sena S, Olive M, Desgranges C, Gadeau A-P. AP-1 is involved in UTP-induced osteopontin expression in arterial smooth muscle cells. Circ Res. 2003;93:674-681.
15. Renault M-A, Jalvy S, Potier M, Belloc I, Genot E, Dekker LV, Desgranges C, Gadeau A-P. UTP induces osteopontin expression through a coordinate action of NFKB, activator protein-1, and upstream stimulatory factor in arterial smooth muscle cells. J. Biol. Chem. 2005;280: 2708-2713.
16. Gomez MF, Stevenson AS, Bonev AD, Hill-Eubanks DC, Nelson MT. Opposing actions of inositol 1,4,5-trisphosphate and ryanodine receptors on nuclear factor of activated T-cells regulation in smooth muscle. J Biol Chem. 2002;277:37756-37764.
17. Liu Z, Dronadula N, Rao GN. A novel role for nuclear factor of activated T cells in receptor tyrosine kinase and G protein-coupled receptor agonist-induced vascular smooth muscle cell motility. J Biol Chem. 2004;279:41218-41226.
18. Nilsson J, Nilsson LM, Chen Y-W, Molkentin JD, Erlinge D, Gomez MF. High glucose activates nuclear factor of activated T cells in native vascular smooth muscle. Arterioscler Thromb Vasc Biol. 2006;26: 794-800.
19. Kawamura H, Yokote K, Asaumi S, Kobayashi K, Fujimoto M, Maezawa Y, Saito Y, Mori S. High glucose-induced upregulation of osteopontin is mediated via Rho/Rho kinase pathway in cultured rat aortic smooth muscle cells. Arterioscler Thromb Vasc Biol. 2004;24:276-281.
20. Nilsson LM, Nilsson-Ohman J, Zetterqvist AV, Gomez MF. Nuclear factor of activated T-cells transcription factors in the vasculature: the good guys or the bad guys? Curr Opin Lipidol. 2008;19:483-490.
21. Lipskaia L, Pourci M-L, Delomenie C, Combettes L, Goudouneche D, Paul J-L, Capiod T, Lompre A-M. Phosphatidylinositol 3-kinase and calcium-activated transcription pathways are required for VLDL-induced smooth muscle cell proliferation. Circ Res. 2003;92:1115-1122.
22. Liu Z, Zhang C, Dronadula N, Li Q, Rao GN. Blockade of nuclear factor of activated T cells activation signaling suppresses balloon injury-induced neointima formation in a rat carotid artery model. J Biol Chem. 2005; 280:14700-14708.
23. Nilsson LM, Sun ZW, Nilsson J, Nordstrom I, Chen YW, Molkentin JD, Wide-Swensson D, Hellstrand P, Lydrup ML, Gomez MF. Novel blocker of NFAT activation inhibits IL-6 production in human myometrial arteries and reduces vascular smooth muscle cell proliferation. Am J Physiol Cell Physiol. 2007;292:C1167-C1178.
24. McDonald OG, Wamhoff BR, Hoofnagle MH, Owens GK. Control of SRF binding to CArG box chromatin regulates smooth muscle gene expression in vivo. J Clin Invest. 2006;116:36-48.
25. 2+ channels modulate expression of smooth muscle differentiation marker genes via a rho kinase/myocardin/SRF-dependent mechanism. Circ Res. 2004;95: 406-414.
26. Heit JJ. Calcineurin/NFAT signaling in the beta-cell: from diabetes to new therapeutics. BioEssays. 2007;29:1011-1021.
27. 2+-dependent NFATc3 nuclear accumulation in vascular smooth muscle: role of JNK2 and Crm-1. J Biol Chem. 2003;278:46847-46853.
28. Gonzalez Bosc LV, Wilkerson MK, Bradley KN, Eckman DM, Hill-Eubanks DC, Nelson MT. Intraluminal pressure is a stimulus for NFATc3 nuclear accumulation: role of calcium, endothelium-derived nitric oxide, and cGMP-dependent protein kinase. J Biol Chem. 2004;279: 10702-10709.
29. Bidder M, Shao J-S, Charlton-Kachigian N, Loewy AP, Semenkovich CF, Towler DA. Osteopontin transcription in aortic vascular smooth muscle cells is controlled by glucose-regulated upstream stimulatory factor and activator protein-1 activities. J Biol Chem. 2002;277: 44485-44496.
30. Asaumi S, Takemoto M, Yokote K, Ridall AL, Butler WT, Fujimoto M, Kobayashi K, Kawamura H, Take A, Saito Y, Mori S. Identification and characterization of high glucose and glucosamine responsive element in the rat osteopontin promoter. J Diabetes Complications. 2003;17:34-38.
31. Orr AW, Lee MY, Lemmon JA, Yurdagul A Jr, Gomez MF, Schoppee Bortz PD, Wamhoff BR. Molecular mechanisms of collagen isotype-specific modulation of smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol. 2009;29:225-231.
32. de Frutos S, Spangler R, Alo D, Bosc LV. NFATc3 mediates chronic hypoxia-induced pulmonary arterial remodeling with alpha-actin up-regulation. J Biol Chem. 2007;282:15081-15089.
33. Nieves-Cintron M, Amberg GC, Nichols CB, Molkentin JD, Santana LF. Activation of NFATc3 down-regulates the beta1 subunit of large conductance, calcium-activated K+ channels in arterial smooth muscle and contributes to hypertension. J Biol Chem. 2007;282:3231-3240.
34. Birsan T, Dambrin C, Marsh KC, Jacobsen W, Djuric SW, Mollison KW, Christians U, Carter GW, Morris RE. Preliminary in vivo pharmacokinetic and pharmacodynamic evaluation of a novel calcineurin-independent inhibitor of NFAT. Transpl Int. 2004;3:145-150.
35. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care. 1995;18:258-268.
36. Davidson JA. Treatment of the patient with diabetes: importance of maintaining target HbA(1c) levels. Curr Med Res Opin. 2004;20: 1919-1927.
37. Yamagishi SI, Nakamura K, Matsui T, Ueda SI, Imaizumi T. Role of postprandial hyperglycaemia in cardiovascular disease in diabetes. Int J Clin Pract. 2007;61:83-87. (Pubitemid 46269354)
38. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615-1625.